ROSGQ (Rosetta Genomics) Days Payable: 216.71 (As of Jun. 2017)


What is Rosetta Genomics Days Payable?

Rosetta Genomics ROSGQ -99.00% Days Payable is 216.71 as of Jun. 2017.

Rosetta Genomics's average Accounts Payable for the six months ended in Jun. 2017 was $1.31 Mil. Rosetta Genomics's Cost of Goods Sold for the six months ended in Jun. 2017 was $1.10 Mil. Hence, Rosetta Genomics's Days Payable for the six months ended in Jun. 2017 was 216.71.

The historical rank and industry rank for Rosetta Genomics's Days Payable or its related term are showing as below:

ROSGQ's Days Payable is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 67.275
* Ranked among companies with meaningful Days Payable only.

Rosetta Genomics's Days Payable declined from Jun. 2016 (252.01) to Jun. 2017 (216.71). It may suggest that Rosetta Genomics accelerated paying its suppliers.

Rosetta Genomics Days Payable Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Days Payable Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 946.45 427.29 204.65 47.52 64.86

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.62 55.55 252.01 34.83 216.71

ROSGQ vs TEAR, IDTA, ABMC: Days Payable Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics Days Payable vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Days Payable distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Days Payable falls into.


Rosetta Genomics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Rosetta Genomics's Days Payable for the fiscal year that ended in Dec. 2016 is calculated as

Days Payable (A: Dec. 2016 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2015 ) + Accounts Payable (A: Dec. 2016 )) / count ) / Cost of Goods Sold (A: Dec. 2016 )*Days in Period
=( (1.07 + 1.574) / 2 ) / 7.439*365
=1.322 / 7.439*365
=64.86

Rosetta Genomics's Days Payable for the quarter that ended in Jun. 2017 is calculated as:

Days Payable (Q: Jun. 2017 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2016 ) + Accounts Payable (Q: Jun. 2017 )) / count ) / Cost of Goods Sold (Q: Jun. 2017 )*Days in Period
=( (1.574 + 1.036) / 2 ) / 1.099*365 / 2
=1.305 / 1.099*365 / 2
=216.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 216.71 mean?
Rosetta Genomics (ROSGQ) has a Days Payable of 216.71 as of Jun. 2017. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Days Payable too high?
Rosetta Genomics' current Days Payable is 216.71. The Medical Diagnostics & Research industry median Days Payable is 67.28. Rosetta Genomics' value of 216.71 is 222.1% above this industry median.
How does Rosetta Genomics' Days Payable compare to TEAR and IDTA?
Rosetta Genomics' Days Payable of 216.71 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Days Payable is 67.28. Rosetta Genomics' value of 216.71 is 222.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rosetta Genomics's current Days Payable of 216.71 is 222.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Days Payable is 216.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Days Payable of 216.71. The current Days Payable is 216.71 and 222.1% above the Medical Diagnostics & Research industry median of 67.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Days Payable is 216.71 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.